Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses. Issue 1 (July 2015)

• Record Type: Journal Article
• Authors: Lebellec, Loïc; Aubert, Sébastien; Zaïri, Fahed; Ryckewaert, Thomas; Chauffert, Bruno; Penel, Nicolas
• Is Part Of: Critical reviews in oncology/hematology. Volume 95:Issue 1(2015)
• Page Start: 125
• Page End: 131
• Publication Date: 2015-07
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2015.01.010
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Chordoma displays several druggable targets.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">The level of evidence supporting the use of molecularly targeted therapies remains low.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Chordoma is an indolent tumour and tumor shrinkage under treatment is rare, classical radiological criteria for activity assessment seem not suitable.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">International collaborative efforts are highly desirable to go further.</p> </list-item> </list> </p> </sec> </abstract>